1. Gharibi T, Barpour N, Hosseini A, Mohammadzadeh A, Marofi F, Ebrahimi-Kalan A, Nejati-Koshki K, Abdollahpour-Alitappeh M, Safaei S, Baghbani E, Baradaran B. STA-21, a
small molecule STAT3 inhibitor, ameliorates experimental autoimmune
encephalomyelitis by altering Th-17/Treg balance. International Immunopharmacology. 2023 Jun 1;119:110160.
2. Barpour N, Ghorbani M, Baradaran B, Jodari-Mohammadpour Z, Nejati-Koshki K, Abdollahpour-Alitappeh M, Dabbaghi R, Gharibi T. Development of an injectable
chitosan-based hydrogel containing Nano-hydroxy-apatite and Alendronate for MSC- based therapy. International Journal of Biological Macromolecules. 27 Jan 2024,
129737.
3. Gharibi T, Hosseini A, MaroH F, Oraei M, Jahandideh S, Abdollahpour-Alitappeh M, et
al. IL-21 and IL-21-producing T cells are involved in multiple sclerosis severity and
progression. Immunology letters. 2019;216:12-20.
4. Gharibi T, Babaloo Z, Hosseini A, Abdollahpour-Alitappeh M, Hashemi V, Marofi F, et al.
Targeting STAT3 in cancer and autoimmune diseases. European Journal of
Pharmacology. 2020:173107.
5. Gharibi T, Babaloo Z, Hosseini A, Marofi F, Ebrahimi?kalan A, Jahandideh S, et al. The
role of B cells in the immunopathogenesis of multiple sclerosis. Immunology. 2020.
6. Gharibi T, Ahmadi M, Seyfizadeh N, Jadidi-Niaragh F, Yousefi M. Immunomodulatory
characteristics of mesenchymal stem cells and their role in the treatment of multiple
sclerosis. Cellular immunology. 2015;293(2):113-21.
7. Gharibi T, Kazemi T, Aliparasti MR, Farhoudi M, Almasi S, Dehghanzadeh R.
Investigation of IL-21 gene polymorphisms (rs2221903, rs2055979) in cases with
multiple sclerosis of Azerbaijan, Northwest Iran. American journal of clinical and
experimental immunology. 2015;4(1):7.
8. Gharibi T, Majidi J, Kazemi T, Dehghanzadeh R, Motallebnezhad M, Babaloo Z. Biological effects of IL-21 on different immune cells and its role in autoimmune
diseases. Immunobiology. 2016;221(2):357-67.
9. Hosseini A, Gharibi T, Mohammadzadeh A, Ebrahimi-Kalan A, Jadidi-Niaragh F, Babaloo Z, Shanehbandi D, Baghbani E, Baradaran B. Ruxolitinib attenuates
experimental autoimmune encephalomyelitis (EAE) development as animal models of
multiple sclerosis (MS). Life Sciences. 2021 Jul 1;276:119395.